FIRST AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT Effective Date: August 2, 2017
Exhibit 10.34
FIRST AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT
Effective Date: August 2, 2017
THIS FIRST AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT (this “Amendment”), is entered into by and between Iovance Biotherapeutics, Inc., a Delaware corporation, successor in interest to Lion Biotechnologies, Inc., with a place of business located at 000 Xxxxxx Xxxx, Xxxxx 000, Xxx Xxxxxx, XX 00000 (“Iovance”), and The University of Texas M. D. Xxxxxxxx Cancer Center, with a place of business located at 0000 Xxxxxxxx Xxxx., Xxxxxxx, XX 00000 (“MD Xxxxxxxx”), a member institution of The University of Texas System, as of the date set forth above (the “Effective Date”). Iovance and MD Xxxxxxxx may each be referred to as a “Party” or together, the “Parties”.
WHEREAS, the Parties have entered into a Strategic Alliance Agreement effective April 17, 2017 (the “Original Agreement”); and
WHEREAS, the Parties now desire to amend the Original Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree to be legally bound as follows:
1. The following sentence in Section 2.1(a) of the Original Agreement:
The first three Study Orders are attached to this Agreement as Exhibit I, Exhibit II, and Exhibit III, and the Studies that are the subject of such Study Orders are also referred to herein as the “Initial Studies”.
is hereby deleted and replaced in its entirety by the following sentence:
The first three Study Orders, when completed, will be incorporated into this Agreement as Exhibit I, Exhibit II, and Exhibit III, and the Studies that are the subject of such Study Orders are also referred to herein as the “Initial Studies”.
2. In the event of any inconsistency or conflict between the terms of this Amendment and the terms of the Original Agreement, the terms of this Amendment shall control.
3. This Amendment, together with the Original Agreement, constitutes the final and complete expression of the parties with respect to the subject matter hereof. This Amendment may not be amended except by a written instrument duly executed and delivered by each of the parties.
4. Except as expressly amended by this Amendment, all of the terms and conditions of the Original Agreement shall remain unchanged and in full force and effect as set forth therein.
5. This Amendment may be executed in any number of counterparts, including by electronic portable document format (PDF) exchange, each of which shall be deemed an original as against any Party whose signature appears thereon, but all of which, taken together, shall constitute one and the same instrument, with the same effect as though such signatures were on the same instrument.
| 1 |
IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the Effective Date.
| IOVANCE BIOTHERAPEUTICS, INC. | THE UNIVERSITY OF TEXAS | |
| M.D. XXXXXXXX CANCER CENTER | ||
| By: /s/ Xxxxx Xxxxxx | By: /s/ Xxxxx XxXxx | |
| Authorized Signature | Authorized Signature | |
| Xxxxx Xxxxxx, Ph.D., M.B.A. | Xxxxx XxXxx | |
| Printed Name | Printed Name | |
| President and Chief Executive Officer | SVP, Strategy & Business Development | |
| Title | Title |
| 2 |
